Highlights
Among 130,277 postmenopausal women in the Women’s Health Initiative, a self-reported physician diagnosis of migraine was associated with a modestly higher risk of incident ischemic stroke over nearly 20 years of follow-up.
The association did not reach statistical significance for total stroke overall after multivariable adjustment, and no significant association was observed for hemorrhagic stroke.
The signal appeared strongest for ischemic stroke subtypes classified as cardioembolic and undetermined, although confidence intervals for these subtype analyses crossed unity.
The excess ischemic stroke risk associated with migraine did not vary significantly across baseline age groups in planned age-stratified analyses.
Background
Migraine has long been recognized as more than a recurrent headache disorder. In women of reproductive age, particularly those with migraine with aura, it has been associated with increased risk of ischemic stroke and with a broader adverse vascular profile. This relationship has influenced counseling on smoking cessation, estrogen-containing contraceptive use, and vascular risk modification in younger women. What has remained less clear is whether migraine continues to carry cerebrovascular relevance after menopause, when endogenous hormonal patterns change, traditional vascular risk factors accumulate, and competing causes of stroke become more common.
This question is clinically important. Stroke incidence rises sharply with age, and women shoulder a substantial burden of stroke-related disability and mortality later in life. At the same time, migraine is common in women across the life course, and a history of migraine often persists in the medical record even when attack frequency decreases after menopause. For clinicians caring for older women, the practical issue is whether migraine history should still be considered a meaningful cerebrovascular risk marker after menopause, and if so, how strongly it should influence prevention strategies.
The new Women’s Health Initiative analysis by Madsen and colleagues addresses this gap using one of the largest and longest-running cohorts of postmenopausal women in the United States. Its central message is nuanced: migraine history in postmenopausal women was linked to higher ischemic stroke risk, but not to hemorrhagic stroke, and not clearly to total stroke overall after full adjustment.
Study Design and Methods
Cohort and population
The investigators analyzed data from the Women’s Health Initiative, a large US longitudinal cohort of postmenopausal women. They included 130,277 participants after excluding women with prior stroke and those missing key baseline data. The median age at baseline was 63 years, with an interquartile range of 57 to 69 years.
The exposure of interest was a self-reported, physician-diagnosed history of migraine at baseline. The primary outcome was incident stroke during follow-up, assessed as total stroke and then separated into ischemic and hemorrhagic stroke. For ischemic stroke, planned secondary analyses further examined subtype categories.
Statistical approach
The authors used multivariable Cox proportional hazards models to estimate cause-specific hazard ratios. Models were adjusted sequentially, first for age, then for traditional cardiovascular risk factors, and finally for female-specific factors including age at menopause, age at menarche, menstrual irregularity, vasomotor symptoms, parity, breastfeeding history, and menopausal hormone therapy use.
This adjustment strategy is a notable feature of the study. Prior work on migraine and stroke has often focused on conventional vascular covariates but has been less attentive to reproductive and menopause-related characteristics. Because menopause timing, hormone exposure, and vasomotor symptoms may themselves be linked to vascular health, including these covariates improves the clinical relevance of the analysis in older women.
The investigators also performed age-stratified analyses in 5-year baseline age groups to test whether any migraine-associated stroke risk was concentrated in younger postmenopausal participants rather than persisting across later ages. Importantly, the study did not have data on aura status or migraine frequency, two factors that would have helped refine risk estimates.
Key Findings
Overall event burden
During a median follow-up of 19.9 years, with an interquartile range of 9.1 to 25 years, 5,743 incident stroke events occurred. This long observation period is a major strength because it captures clinically meaningful vascular outcomes across late midlife and older age.
Total stroke
In fully adjusted analyses, migraine history was not significantly associated with total stroke. The hazard ratio was 1.07, with a 95% confidence interval of 0.99 to 1.17. This point estimate suggests a small possible increase in overall stroke risk, but the confidence interval includes 1.0, meaning the result did not meet conventional thresholds for statistical significance.
For clinicians, this is an important distinction. If migraine were associated with all stroke types combined to a clinically large degree, one might expect a clearly elevated total stroke signal. Instead, the neutral total stroke result suggests that any excess risk is modest and likely specific to certain stroke mechanisms rather than a broad increase in cerebrovascular events.
Ischemic stroke
The most clinically relevant finding was the significant association between migraine history and ischemic stroke. The fully adjusted hazard ratio was 1.12, with a 95% confidence interval of 1.02 to 1.23. Although the effect size is modest, the association remained after accounting for traditional cardiovascular factors and female-specific reproductive variables.
This result suggests that migraine history may function as a risk marker for ischemic stroke in postmenopausal women, even if the absolute increase in risk for an individual patient is not large. From a prevention standpoint, the finding does not imply that migraine is a dominant driver of stroke in older women. Rather, it supports including migraine history in the broader risk conversation, especially when other vascular risk factors are present.
Ischemic stroke subtype analyses
In planned secondary analyses, the association appeared most pronounced for cardioembolic ischemic stroke and stroke of undetermined cause. The hazard ratio for cardioembolic stroke was 1.17, with a 95% confidence interval of 0.98 to 1.39. For undetermined ischemic stroke, the hazard ratio was 1.14, with a 95% confidence interval of 0.98 to 1.33.
These subtype estimates did not cross the conventional statistical threshold because their confidence intervals included 1.0. Nonetheless, the pattern is potentially informative. A cardioembolic signal raises the possibility that some of the migraine-stroke relationship in later life may intersect with atrial or structural cardiac mechanisms, occult embolic phenomena, or shared vascular susceptibilities rather than exclusively with small-vessel disease. Because the confidence intervals are wide and overlapping, these subtype findings should be interpreted as hypothesis-generating rather than definitive.
Hemorrhagic stroke
Migraine history was not associated with hemorrhagic stroke. The hazard ratio was 0.85, with a 95% confidence interval of 0.67 to 1.09. This neutral finding is clinically reassuring and suggests that the vascular relevance of migraine in this population is not generalized across all forms of stroke.
The absence of a hemorrhagic association also helps contextualize the total stroke result. If migraine selectively increases ischemic events but not hemorrhagic events, the combined endpoint of total stroke may dilute the apparent effect.
Age-stratified results
The study did not find significant variation in migraine-associated total stroke risk across baseline age groups. In practical terms, the data do not support the notion that migraine-related cerebrovascular risk is limited to the youngest segment of postmenopausal women. However, because age-stratified analyses can be underpowered for modest effects, especially within narrower age bands, a lack of heterogeneity should not be overinterpreted as proof of identical risk at all ages.
Clinical Interpretation
The main clinical takeaway is that migraine history remains relevant after menopause, but in a targeted way. It appears to mark a modest increase in ischemic stroke risk rather than a broad increase in all stroke types. This matters because stroke prevention in older women is increasingly individualized, integrating traditional risk factors such as hypertension, diabetes, dyslipidemia, smoking, atrial fibrillation, and obesity with sex-specific and life course factors.
Where should migraine fit in that framework? Probably as a risk-enhancing factor rather than a stand-alone determinant. The observed hazard ratio of 1.12 for ischemic stroke is too small to justify disease-specific intervention on its own, but it is large enough to support heightened attention to aggressive risk factor management. In a postmenopausal woman with migraine history and borderline vascular risk, clinicians may reasonably place greater emphasis on blood pressure control, smoking avoidance, physical activity, weight management, diabetes screening, and evaluation for atrial arrhythmia when otherwise indicated.
The findings are also relevant to menopause care. The investigators adjusted for menopausal hormone therapy, but the study was not designed to test whether hormone use modifies migraine-associated stroke risk. Therefore, these results should not be used to make direct treatment decisions about hormone therapy in individual patients. Still, they reinforce the broader principle that vascular risk assessment in postmenopausal women should integrate neurologic history, reproductive history, and conventional cardiovascular factors rather than treating these domains separately.
Mechanistic Considerations
Several biological pathways could plausibly link migraine to ischemic stroke in older women. In younger populations, proposed mechanisms include endothelial dysfunction, altered vascular reactivity, prothrombotic states, cortical spreading depolarization, paradoxical embolism through patent foramen ovale, and shared genetic susceptibility. In postmenopausal women, these pathways may intersect with age-related atrial fibrillation, atherosclerosis, and cumulative vascular injury.
The suggestion of stronger associations for cardioembolic and undetermined ischemic stroke is intriguing. It may reflect unmeasured cardiac rhythm disorders, embolic sources not fully captured at the time of stroke classification, or residual confounding by vascular comorbidity. Another possibility is that migraine history identifies a subgroup with persistent vascular vulnerability that becomes clinically expressed through common late-life stroke mechanisms rather than through mechanisms unique to migraine itself.
Because aura status was unavailable, the study cannot answer whether the excess ischemic risk is confined mainly to women with migraine with aura, as has often been observed in younger cohorts. That missing information is central to mechanism as well as to clinical translation.
Strengths and Limitations
Strengths
This study has several major strengths. First, its sample size was large, and the number of outcome events substantial. Second, follow-up was unusually long, providing a robust view of late-life stroke incidence. Third, the use of sequential multivariable models allowed assessment of whether reproductive and menopause-related factors materially altered the migraine-stroke association. Fourth, the focus on postmenopausal women fills an important evidence gap not addressed by many earlier migraine-stroke studies.
Limitations
The limitations are equally important. Migraine exposure was based on self-reported physician diagnosis at baseline, which introduces potential misclassification. The study lacked information on migraine aura, attack frequency, duration, change in migraine pattern over time, and acute or preventive migraine treatments. These omissions matter because aura is the migraine feature most consistently linked to ischemic stroke in prior literature.
Residual confounding is possible, as in any observational cohort, even with careful adjustment. Factors such as atrial fibrillation burden, sleep disorders, inflammatory states, medication use over time, and socioeconomic influences may not have been fully captured. The subtype analyses for ischemic stroke are interesting but not definitive, as the confidence intervals crossed unity. Finally, the study establishes association, not causation. Migraine may be a marker of underlying vascular susceptibility rather than a direct biological cause of stroke.
How This Fits With Prior Evidence
Prior meta-analyses have generally shown that migraine, especially migraine with aura, is associated with ischemic stroke in women, with the clearest signal in younger and midlife populations. The present analysis extends that literature by showing that the association does not necessarily disappear after menopause. At the same time, the effect size in this older cohort is more modest than the relative risks reported in some younger populations, which is biologically and epidemiologically plausible as competing vascular risks accumulate with age.
Current stroke prevention frameworks increasingly recognize female-specific risk factors and sex differences in vascular disease. This study supports the view that a history of migraine belongs in that conversation, even if it is not yet incorporated into formal risk calculators for older women.
Practice Implications
For clinicians, the study does not suggest a need for routine stroke-specific imaging or anticoagulation simply because a postmenopausal woman has a migraine history. It does, however, support asking about migraine as part of vascular risk assessment and documenting it as one piece of a woman’s life course cerebrovascular profile.
Patients with migraine history should receive evidence-based counseling on modifiable stroke risks. Particular attention should be paid to hypertension control, smoking avoidance, physical activity, lipid management, diabetes prevention or treatment, and recognition of atrial fibrillation when symptoms or screening context warrant. In women considering menopausal hormone therapy, migraine history should be weighed alongside overall vascular risk, although this study alone cannot define treatment thresholds.
Conclusion
In the Women’s Health Initiative, postmenopausal women with a history of migraine had a modest but statistically significant increase in ischemic stroke risk over nearly two decades of follow-up. Migraine was not significantly associated with total stroke after full adjustment and was not linked to hemorrhagic stroke. These findings support viewing migraine history as a risk marker for ischemic stroke in postmenopausal women rather than as a universal marker of cerebrovascular risk.
The practical implication is measured but meaningful: migraine history should inform, not dominate, stroke prevention discussions after menopause. Future work should clarify the role of migraine aura, treatment exposure, cardiac rhythm disorders, and imaging-defined vascular phenotypes in explaining this association and in identifying which older women with migraine are at clinically important excess risk.
Funding and Trial Information
The abstract provided does not list specific funding details for this analysis. The Women’s Health Initiative is a longstanding US research program supported by the National Heart, Lung, and Blood Institute. No ClinicalTrials.gov identifier was provided in the source abstract, and this observational cohort analysis should be cited according to the published Neurology report.
References
1. Madsen TE, Raker CA, Pavlovic JM, Harrington LB, Schnatz PF, Stefanick ML, Allison M, Shadyab AH, Liu S, Penzien DB, Haring B, Wild RA, Liu L, Saquib N, Wactawki-Wende J, Ikramuddin F, LaMonte MJ, Manson JE, Silver B. Migraine and Stroke Risk in Postmenopausal Women in the Women’s Health Initiative. Neurology. 2026-06-05;107(1):e214825. PMID: 42247650.
2. Sacco S, Ornello R, Ripa P, Pistoia F, Carolei A. Migraine and risk of ischaemic heart disease: a systematic review and meta-analysis of observational studies. Eur J Neurol. 2015;22(6):1001-1011.
3. Mahmoud AN, Mentias A, Elgendy AY, Qazi A, Barakat AF, Saad M, Mohsen A, Abuzaid A, Elgendy IY, Mojadidi MK. Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. BMJ Open. 2018;8(3):e020498.
4. Bushnell C, McCullough LD, Awad IA, Chireau MV, Fedder WN, Furie KL, Howard VJ, Lichtman JH, Lisabeth LD, Piña IL, Reeves MJ, Rexrode KM, Saposnik G, Singh V, Towfighi A, Vaccarino V, Walters MR. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(5):1545-1588.
5. The Women’s Health Initiative Study Group. Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19(1):61-109.
